A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Iovance Biotherapeutics, Inc.
Study ID
NCT07288203
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Lifileucel — BIOLOGICAL
    A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.

Study Details

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma

Key Dates

Start date
Nov 28, 2025
Status verified
Apr 2026
Primary completion
Dec 31, 2032
Completion
Dec 31, 2033

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Lifileucel

Primary Outcome Measure

Objective Response Rate [ Time Frame: 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Sarah Cannon Research InstituteNashvilleTennessee37203-

Find similar trials in Nashville, TN

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Sarah Cannon Research Institute· Nashville, TN

Related Studies